Role will drive growth, focus Babyscripts’ strategic expansion in payer and provider markets
Awarded $15 million grant from CIRM to support the KPI-012 PCED program
Topline data from the trial are expected in the first half of 2024
Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
Data demonstrated the absorption and shedding of SPVN06, which was transiently observed in blood and tears, and high tropism for the retina
Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment
Company Appoints De Novo Ventures Co-Founder Richard Ferrari as Chairperson, and Names Hendrik Lambert, PhD., as Chief Medical Officer
Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes
Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy or the treatment of persistent corneal epithelial defect
Subscribe to our weekly newsletter for the latest updates on life sciences investments.